# A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia

> **NCT06859073** · PHASE1 · RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 60 (estimated)

## Conditions studied

- Healthy Volunteers
- Hyperuricemia

## Interventions

- **DRUG:** NNC4004-0002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06859073
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-13
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06859073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06859073, "A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06859073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*